We are live on
!
Find out more
AQR Capital Management Portfolio holdings
AUM
$218B
1-Year Est. Return
29.41%
This Fund
S&P 500
This Quarter
Est. Return
-12.77%
1 Year Est. Return
+29.41%
3 Year Est. Return
+92.15%
5 Year Est. Return
+116.61%
10 Year Est. Return
+435.72%
AUM
$44.2B
AUM Growth
-$8.44B
(-16%)
Cap. Flow
-$301M
Cap. Flow
% of AUM
-0.68%
Top 10 Holdings %
Top 10 Hldgs %
14.01%
Holding
2,360
New
150
Increased
1,005
Reduced
998
Closed
187
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Gilead Sciences
GILD
|
+$209M |
| 2 |
CVS Health
CVS
|
+$195M |
| 3 |
Tyson Foods
TSN
|
+$136M |
| 4 |
ExxonMobil
XOM
|
+$135M |
| 5 |
LyondellBasell Industries
LYB
|
+$130M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Thermo Fisher Scientific
TMO
|
+$239M |
| 2 |
Microsoft
MSFT
|
+$204M |
| 3 |
Johnson & Johnson
JNJ
|
+$157M |
| 4 |
Amazon
AMZN
|
+$144M |
| 5 |
Walmart Inc
WMT
|
+$137M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 20.23% |
| 2 | Healthcare | 16.49% |
| 3 | Financials | 11.74% |
| 4 | Industrials | 11.47% |
| 5 | Consumer Discretionary | 10.94% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
376
Medpace
MEDP
$16.8B
| $28.8M | 0.07% |
194,653
-20,003
| -9% | -$2.9M |
|
377
Associated Banc-Corp
ASB
$5.92B
| $28.8M | 0.07% |
1,598,710
+270,993
| +20% | +$5.48M |
|
378
NorthWestern Energy
NWE
$4.38B
| $28.7M | 0.07% |
489,611
+210,531
| +75% | +$12.5M |
|
|
LSI
379
DELISTED
Life Storage, Inc.
LSI
| $28.6M | 0.06% |
257,394
+46,711
| +22% | +$5.77M |
|
380
Parker-Hannifin
PH
$134B
| $28.2M | 0.06% |
116,618
+20,397
| +21% | +$5.46M |
|
381
Evercore
EVR
$11.5B
| $28.1M | 0.06% |
302,845
+9,151
| +3% | +$975K |
|
382
Dropbox
DBX
$8.07B
| $28.1M | 0.06% |
1,353,826
+82,011
| +6% | +$1.77M |
|
383
Navient
NAVI
$796M
| $28M | 0.06% |
2,033,937
+1,036,333
| +104% | +$16.1M |
|
384
West Pharmaceutical
WST
$24.8B
| $27.9M | 0.06% |
94,055
-11,090
| -11% | -$3.61M |
|
385
HF Sinclair
DINO
$15.2B
| $27.8M | 0.06% |
616,447
-621,902
| -50% | -$27.9M |
|
386
Curtiss-Wright
CW
$25.6B
| $27.8M | 0.06% |
215,447
+44,636
| +26% | +$6.34M |
|
387
EPAM Systems
EPAM
$5.02B
| $27.8M | 0.06% |
94,835
-231,193
| -71% | -$70.6M |
|
388
Cintas
CTAS
$81.1B
| $27.6M | 0.06% |
299,528
-78,452
| -21% | -$7.64M |
|
389
Public Service Enterprise Group
PEG
$37.2B
| $27.6M | 0.06% |
442,254
+2,436
| +0.6% | +$166K |
|
390
Lithia Motors
LAD
$8.35B
| $27.6M | 0.06% |
100,357
-6,499
| -6% | -$1.89M |
|
391
JetBlue
JBLU
$2.13B
| $27.6M | 0.06% |
3,291,992
+1,858,514
| +130% | +$19.9M |
|
392
Terex
TEX
$7.58B
| $27.5M | 0.06% |
1,029,000
+180,712
| +21% | +$6.02M |
|
393
Nike
NKE
$62.5B
| $27.5M | 0.06% |
271,852
-696,267
| -72% | -$82.3M |
|
394
SEI Investments
SEIC
$12.6B
| $27.5M | 0.06% |
514,995
-59,877
| -10% | -$3.37M |
|
395
Brighthouse Financial
BHF
$3.46B
| $27.4M | 0.06% |
681,012
+133,057
| +24% | +$6.42M |
|
|
BNY
396
Bank of New York Mellon
BNY
$108B
| $27.4M | 0.06% |
664,593
+152,940
| +30% | +$6.81M |
|
397
AXIS Capital
AXS
$7.43B
| $27.2M | 0.06% |
483,034
-11,735
| -2% | -$669K |
|
398
NVR
NVR
$16.8B
| $27M | 0.06% |
6,877
-1,724
| -20% | -$7.34M |
|
399
Equinix
EQIX
$103B
| $26.9M | 0.06% |
41,371
-18,190
| -31% | -$12.6M |
|
400
Concentrix
CNXC
$1.56B
| $26.9M | 0.06% |
200,553
-61,986
| -24% | -$9.33M |
|
Similar funds
VGA
AQR Capital Management's Q2 2022 Portfolio in Review
As of Q2 2022, AQR Capital Management held 2,360 positions worth $44.2B, down 16% from $52.7B the previous quarter. Its ten largest holdings account for 14% of the portfolio.
AQR Capital Management's Q2 2022 filing shows 150 new, 1,005 increased, 998 reduced and 187 closed positions. Its largest new stake was Fluor: 339,891 shares worth $7.86M. The largest sale was Thermo Fisher Scientific, an estimated $239M.
By sector, the portfolio is most concentrated in Technology at 20% of assets, down from 23% a quarter earlier, followed by Healthcare and Financials.
- AQR Capital Management's largest Q2 2022 buy was Fluor: 339,891 shares worth $7.86M.
- AQR Capital Management added most to Gilead Sciences in Q2 2022, an estimated $209M increase.
- AQR Capital Management's biggest Q2 2022 reduction was Thermo Fisher Scientific, cutting an estimated $239M.
- AQR Capital Management fully exited Roku in Q2 2022, selling an estimated $32.5M.
- AQR Capital Management's ten largest holdings make up 14% of its $44.2B portfolio in Q2 2022.
- AQR Capital Management opened 150 new positions and closed 187 in Q2 2022.
- AQR Capital Management's portfolio value fell 16% quarter-over-quarter to $44.2B.
Based on AQR Capital Management's 13F filing for Q2 2022, filed 15 Aug 2022.